Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound
| | | |

Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound

On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State…